Floatz logo

Mirvetuximab Soravtansine

BRCA2 Gene Mutation

Ohio State University Comprehensive Cancer Centerantibody_drug_conjugatePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

31 Active assets in the BRCA2 Gene Mutation cohort.

Asset / SponsorPhaseRating
Olaparib
M.D. Anderson Cancer Center
Phase 3BB
Veliparib
The University of Texas Health Science Center at San Antonio
Phase 2BB
Olaparib
GBG Forschungs GmbH
Phase 3BB
Talzenna
Brown University
Phase 3BB
Ovitrelle
University Hospital, Ghent
Phase 4BB

View all 50 →

Same molecule, other indications

Mirvetuximab Soravtansine is also rated in:

ovarian carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
fallopian tube cancerDormant
BB
Indicative ·
70 / 100
View asset →
primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →